logo
Night Shifts May Raise Your Asthma Risk—If You're a Woman

Night Shifts May Raise Your Asthma Risk—If You're a Woman

Gizmodo5 hours ago

Asthma is a chronic respiratory disease that often causes sudden and intense shortness of breath. The disease impacts around 339 million people worldwide, and in the U.S. nine people on average die from asthma every day.
Researchers in the U.K. have found that women who work night shifts are more likely to have moderate or severe asthma than women who work during the day. The study, published Monday in the journal ERJ Open Research, does not reveal any such tendency in men working nightshifts, and could hold important implications for public health guidance.
The team had previously shown that permanent night shift workers in general are more likely to suffer from moderate-severe asthma compared to day workers. Scientists also know that asthma is more prevalent and severe in adult women than adult men. 'Since increasing numbers of females are becoming shift workers it is important to determine if shift work-associated asthma risk is higher in females,' the researchers wrote in the study. Shift work refers to scheduled working periods that fall outside of traditional daytime hours. 'Our main aim was to investigate sex differences in the association between shift work and asthma.'
The researchers did so by analyzing data belonging to over 274,541 working people from the U.K. Biobank, a biomedical database open to health researchers. From this initial pool, they found that 5.3% had asthma, and 1.9% of those had moderate or severe asthma. The team then looked into whether the people in these categories worked during the day, during nightshifts, or a mix of both.
The researchers found that female shift workers in general are more likely to suffer from asthma, and women who only work nightshifts have 50% higher likelihood of developing moderate or severe asthma than female daytime workers. Furthermore, the risk increases 'with both number of monthly night shifts and longer lifetime duration of night shift work,' they explained. Interestingly, the data did not reveal any differences in the prevalence of asthma in men based on their work schedule.
'This type of research cannot explain why shift work and asthma are linked,' Robert Maidstone, a co-author of the study and a researcher at the University of Manchester's School of Biological Sciences, said in a university statement. 'However, it could be because shift work disrupts the body clock, including the levels of male and female sex hormones. High testosterone has previously been shown to be protective against asthma, and so lower testosterone in women could play a role. Alternatively, men and women work different types of shift jobs, and this could be a factor.'
Among women not taking hormone replacement therapy (HRT, a treatment for menopausal symptoms), postmenopausal women working only night shifts were almost twice as likely to have moderate-severe asthma than female day workers. This suggests that HRT might protect nightshift workers from asthma, though the researchers admit that more studies are needed to confirm this.
'This research suggests that working nightshifts could be a risk factor for asthma in women, but not in men. The majority of workers will not have an easy option of switching their shift pattern, so we need further research to verify and understand this link and find out what could be done to reduce the risk for women who work shifts,' explained Florence Schleich from the European Respiratory Society, who was not involved in the study.
Moving forward, the researchers aim to investigate how sex hormones might influence asthma prevalence among shift workers. Perhaps this line of research will also shed light on what drives the respiratory disease, given that the exact cause remains a mystery.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lego Is Making an Official Godzilla Set
Lego Is Making an Official Godzilla Set

Gizmodo

time25 minutes ago

  • Gizmodo

Lego Is Making an Official Godzilla Set

Lego's Ideas program has been churning out delightful kits based on fan-submitted (and community-supported) designs for years now, to the point that the brick-maker has quite the hefty list of sets that have hit the necessary 10,000 community backers to eligible for review. Case in point? Today Lego announced the results of its review for the batch of sets to hit that threshold back at the end of last year: and the winners are a doozy. Today Lego confirmed that its latest batch of reviews concluded with two fan-designed sets approved to be made into Lego Ideas sets for general release. The first, by Alexis Dos Santos, is a classic rocket ship build inspired by The Adventures of Tintin, from the beloved comic story 'Destination Moon', where Tintin and his friends help a professor on a top-secret mission to develop the first man-made mission to the moon. The second, however, is a big one, in a literal and metaphorical sense: Matthew Esposito's submission for a massive, brick-built Godzilla. Inspired by the design seen in Legendary's Monsterverse, Esposito's initial Godzilla design had initially been submitted for review back in February 2023, when it initially hit the required 10,000 votes to be considered for review—but after Lego updated the rules for Ideas projects in September 2024 to allow for larger, more detailed set designs, MattE720 resubmitted an even bigger Godzilla design, which once again quickly re-earned 10,000 backers to go forward to Lego's review stage. Although there will be changes made between the submitted design and the eventual official set released by Lego, Esposito's design is markedly impressive for its size and scope, featuring plenty of textured detail to replicate Godzilla's skin, an opening mouth, and even a brick-built effects piece replicating his atomic breath attack. Time will tell just how grand Lego's official spin on it will be, but it's good to see that Godzilla is stomping his way into Lego regardless. There's currently no expected release date for when either the the Tintin Space Rocket or Godzilla sets just yet, and no details on just how much either will cost—but you can start building a titan-shaped dent in your wallet either way.

Integrating CAR T and Bispecific Antibodies in MM Treatment
Integrating CAR T and Bispecific Antibodies in MM Treatment

Medscape

time43 minutes ago

  • Medscape

Integrating CAR T and Bispecific Antibodies in MM Treatment

MILAN — The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has shifted dramatically with the emergence of immunotherapies such as chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (bsAbs). These novel approaches have delivered unprecedented outcomes in heavily pretreated patients. Yet determining the optimal treatment strategy remains a clinical challenge. Here at the 2025 European Hematology Association (EHA) Annual Meeting in Milan, Italy, leading experts weighed the strengths and limitations of both approaches, emphasizing that it is not a contest of superiority but a question of sequence and patient selection. Bispecific Antibodies: Off-the-Shelf Convenience With Strong Responses BsAbs work by redirecting T cells toward myeloma cells, binding simultaneously to a tumor antigen and CD3. In his presentation, Philippe Moreau, MD, head of the hematology department at the University Hospital of Nantes, France, reviewed the four agents approved in Europe: teclistamab, elranatamab, and linvoseltamab, which target beta cell maturation antigen (BCMA); and talquetamab, which targets G protein-coupled receptor class C group 5 member D (GPRC5D). These agents deliver overall response rates (ORRs) of 60%-70% in heavily pretreated patients, with median progression-free survival (PFS) of 12-18 months and overall survival (OS) of 24-30 months. Talquetamab in particular induces rapid responses within 1 month but is associated with unique toxicities — such as skin reactions, dysgeusia, and mucosal effects — related to GPRC5D expression in nonhematopoietic tissues like skin. BsAbs offer immediate treatment without the delays associated with CAR T manufacturing. They are also viable for frail patients and more broadly accessible outside of specialized centers. Toxicities, including cytokine release syndrome and infections, are generally manageable with step-up dosing and prophylactic tocilizumab. However, resistance remains a main concern. Roughly one third of patients — particularly those with high-risk cytogenetics, International Staging System stage III disease, or extramedullary disease — exhibit primary resistance. CAR T-Cell Therapy: Durable Outcomes With Earlier Use CAR T-cell therapies have redefined expectations in RRMM, particularly with ciltacabtagene autoleucel, which has achieved a median PFS of 35 months and a median OS approaching 61 months in heavily pretreated populations. Notably, recent data show that one third of patients remain progression-free at 5 years: an unprecedented milestone. 'Phase 3 trials now show improved PFS, OS, and quality of life compared to standard-of-care regimens,' said Paula Rodriguez-Otero, MD, medical coordinator of the Central Unit for Clinical Trials at the University of Navarra, Pamplona, Spain. However, CAR T therapy faces logistical hurdles, including manufacturing delays and the need for specialized infrastructure. High-risk patients with rapid progression or poor bridging therapy responses may still experience suboptimal results, but these challenges are mitigated when CAR T therapy is used earlier in the disease course, before T-cell exhaustion occurs. It's Not One or the Other Both speakers agreed that the future of MM treatment is not about choosing between CAR T and bsAbs but about defining the optimal sequence and integrating both modalities based on patient needs and disease features. BsAbs offer fast, outpatient-ready options for frail or rapidly progressing patients. CAR T therapies, though more complex, offer long remissions and potential treatment-free intervals, especially when used early. Still, Moreau cautioned, many questions remain. What is the best treatment sequence? Should clinicians switch targets — for example from BCMA to GPRC5D — or stick with the same? How should resistance mechanisms, such as antigen loss, be tackled? Can we move toward fixed-duration therapy to reduce costs? Scientific progress must also account for patient priorities. As Solène Clavreul, PhD, noted in an interview with Medscape Medical News , longer survival for myeloma patients means that quality of life is increasingly central. Clavreul is patient advocate and head of medical education and scientific engagement at Myeloma Patients Europe. 'The treatment choices should always be based on research data, but understanding patients' preferences is critical for shared decision-making,' she said. What's Next: BsAb Combinations and Trispecifics 'With 19 new drugs or combinations approved in the past two decades, we've made incredible progress,' said Jesús San Miguel Izquierdo, MD, PhD, director of clinical and translational medicine at the University of Navarra, Pamplona, Spain, in his EHA 2025 Lifetime Achievement Award lecture. Two industry-sponsored studies presented at EHA 2025 point to the next wave of innovation. RedirecTT-1: Dual-Antigen BsAb Combination The phase 2 RedirecTT-1 trial evaluated the combination of talquetamab and teclistamab in patients with extramedullary disease. 'Patients with true extramedullary disease are up to 87% less likely to respond to conventional therapy,' said Shaji Kumar, MD, consultant, professor, and researcher at the Mayo Clinic, Rochester, USA. The combination treatment in the trial yielded an ORR of 78.9% and a complete response rate of 54.4%, with a 12-month PFS rate of 61% and OS rate of 74.5%. Adverse events were not significantly higher than in monotherapy trials, and less frequent dosing (biweekly or monthly) improved tolerability. 'These results showed deep and durable responses in a population with a significant unmet need,' Kumar said. Moreau, who was not involved in the study, added, 'This could be the pivotal trial that leads to approval of the first bsAb combination.' JNJ-5322: First-in-Human Trispecific Antibody JNJ-5322, a trispecific antibody targeting both BCMA and GPRC5D, showed remarkable efficacy in BCMA/GPRC5D-naive patients in a phase 1 trial. 'Despite recent progress, we still need to reduce treatment burden and improve outcomes,' said Rakesh Popat, MD, hematologist at University College Hospital, London, UK. Among patients with triple-class exposed RRMM, the ORR was 100%, with a 70.4% complete response rate and 12-month PFS of 95%. Grade 3/4 infections occurred in 28.6% of patients, but the safety profile — including mild cytokine release syndrome — was manageable. 'JNJ-5322 demonstrated manageable safety and an ORR comparable to CAR T, with convenient, off-the-shelf, weekly dosing, with one step-up dosing to facilitate outpatient dosing,' Popat concluded. Popat, Clavreul, and Kumar reported no relevant financial relationships. Moreaureported honoraria from and advisory board memberships with Janssen, Celgene, Takeda, Amgen, AbbVie, Sanofi, Pfizer, and GSK. Rodriguez Otero reported honoraria from lectures from BMS-Celgene, J&J Innovative Medicines, Sanofi, GSK, Regeneron, and Pfizer; participation in Ad Board meetings for BMS, Janssen, Sanofi, Oncopeptides, Pfizer, Roche, Regeneron, AbbVie, AstraZeneca, H3 Biomedicine, and GSK; consultancy work for BMS-Celgene, AbbVie, Roche, J&J Innovative Medicines, and Pfizer; and research funding and travel support from Pfizer. San Miguel Izquierdo reported participation on advisory boards and consulting services, on behalf of his institution, for AbbVie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, Secura Bio, and Gilead-Kite. The two industry-sponsored studies mentioned were funded by Johnson & Johnson.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store